Cartesian Therapeutics

RNAC · NASDAQ

$6.40+$0.315 (+5.18%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.08

RNAC analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $34.34 (+437.0% upside)

Low: $16.16
Now: $6.40
High: $46.20

Upgrades and downgrades

The latest rating actions, newest first

RNAC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 30, 2026	Maintains	Buy	$25.00	32%
Needham	Sep 29, 2026	Maintains	Buy	$40.00	38%
Wedbush	Aug 18, 2026	Maintains	Outperform	$38.00	40%
Wedbush	Jun 10, 2026	Maintains	Outperform	$38.00	40%
Needham	Jun 9, 2026	Maintains	Buy	$40.00	38%
BTIG	Jun 9, 2026	Maintains	Buy	$44.00	34%
Wedbush	May 27, 2026	Maintains	Outperform	$38.00	40%
Needham	May 26, 2026	Maintains	Buy	$42.00 → $40.00	38%
HC Wainwright & Co.	May 12, 2026	Maintains	Buy	$30.00 → $25.00	32%
Wedbush	May 1, 2026	Maintains	Outperform	$38.00	40%

The case for and against

Updated Oct 14, 2026

Bull case

Cartesian Therapeutics is supported by a compelling repeat-dosing profile for Descartes-08, as 5 re-treated patients achieved mean 12-month MG-ADL and MGC reductions of 6.6 and 15.0 points, with 4/5 maintaining at least a 2-point MG-ADL improvement and no CRS, ICANS, cytopenias, or hypogammaglobulinemia. The company’s chemo-free, outpatient mRNA platform could differentiate it from conditioning-dependent CAR-T and chronic maintenance therapies by enabling intermittent courses that restore durable benefit without cumulative toxicity, while also expanding use in patients unsuitable for lymphodepletion. With a cash position over $4.50/sh and multiple 1H27 catalysts ahead, including AURORA topline data, the clinical readthrough and favorable safety profile underpin a positive fundamental outlook.

Bear case

Cartesian Therapeutics is a clinical-stage company with no established commercial revenue base, leaving its valuation heavily dependent on Descartes-08 and a 35% probability of approval in MG rather than proven operating performance. The DCF framework still implies only ~$1,068M of enterprise value despite favorable assumptions, underscoring how fragile the investment case is if clinical data disappoints, trials slip, or safety issues emerge. Long-term dilution, regulatory delays, manufacturing and shipment challenges, and competition from current and future therapies further weaken the fundamental outlook and raise financing and execution risk.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.